Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.

Systematic reviews

Volumn 2, Issue , 2013, Pages 47-

  Tricco, Andrea C ^a   Antony, Jesmin ^b   Soobiah, Charlene ^b   Hemmelgarn, Brenda ^b   Moher, David ^b   Hutton, Brian ^b   Yu, Catherine H ^b   Majumdar, Sumit R ^b   Straus, Sharon E ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; HUMAN; LITERATURE; META ANALYSIS (TOPIC); METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SAFETY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; SAFETY;

MLCS; MLOWN;

EID: 84885430344     PISSN: None     EISSN: 20464053     Source Type: None    
DOI: 10.1186/2046-4053-2-47     Document Type: Article

References (0)